Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
Recurrence of GA following cancer treatment should signal the possibility of cancer recurrence.
TNFi treatment is not associated with increased risk for cancer recurrence in patients with rheumatoid arthritis
Tumor cell lines derived from single cells and curated at different reference labs have quietly evolved in vitro, accumulating distinct genomic aberrations.
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Though it is clear that cancer is associated with an extreme financial burden, the extent of the burden varies widely.
There is concern that added nitrates and nitrites are associated with an increased risk of cancer, but epidemiologic data have been inconclusive thus far.
A meta-analysis of 20 randomized clinical trials found that men may infer a greater benefit from immune checkpoint inhibition.
From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.
There has been little historical evidence to show whether modifying per capita use of alcohol and/or tobacco could affect the cancer mortality rate.
The subtle differences within subsets of populations could tell researchers more about how some cancers affect distinct racial or ethnic populations across a heterogeneous group of minorities.
The mechanisms that drive this benefit are not well-understood, and it is believed that the benefit is not just a result of reducing risk factors such as body weight.
Close postmarketing monitoring will be especially crucial for drugs approved with a breakthrough therapy designation, as many of them were given a pass on the basis of a single pivotal trial.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Drug developers relying on CRISPR-Cas9 platforms for the creation of gene therapies saw their shares slide when it was revealed that the technique may inadvertently cause disruptions of larger chunks of DNA than previously thought.
Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.
Colorectal cancer treatment regimen chart.
Non-small cell lung cancer (NSCLC) treatment regimen chart.
Approved prostate cancer drug treatments including formulations and usual dosing.
An overview of the research regarding the use of massage to improve cancer- or treatment-related symptoms and overall quality of life for patients with cancer.
According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
An analysis of population data on cancer incidence, survival, and mortality revealed that early interventions and improvements to treatments contributed to a 26% decline in cancer deaths from 1991 to 2015.
Examining the costs and benefits of repurposing sildenafil as a cancer medication.
Results from postmarketing trials for drugs approved through FDA's accelerated approval pathway need to be produced in a more timely fashion to reveal the true benefit — or lack thereof — of the drugs approved through these expedited channels.
Multiple studies have examined the possible association between cell phone usage and increased cancer risk, but study designs, potential biases, and interpretations of statistical outcomes leave conclusions uncertain.
Q&A With Frank Luh, MD, MS, MHA and Yun Yen, MD, PhD, FACP: Looking to Broaden CMS Coverage for NGS TestsJuly 04, 2018
Restricting use to FDA-approved NGS tests is not an absolute rule that must last forever. But it's a good start, say two physicians.
There is a paucity of data regarding the long-term endocrine effects of cancer in adolescent and young adult survivors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards
- Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia
- In Search of the Right Sequence for Venetoclax in CLL
- Depression as a Side Effect: Exploring a Link Between Certain Cancer Treatments and Mental Health
- FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer